Experts recommend following sun-safe habits and consulting professionals before use
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
', '
A solution can look clear while still having degraded or lost a trustworthy storage history
Compared to patients who took metformin, statins, insulin or aspirin, there was a unanimous reduction in the risk of developing dry AMD by patients who took GLP-1 receptor agonists
Yes, many providers allow patients to remain at a lower dose, such as 0.5 mg or 1.0 mg, if they are seeing consistent results and have no desire to increase
